Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04815005

HoFH, the International Clinical Collaborators Registry

HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
University of Pennsylvania · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.

Detailed description

The HICC registry is an observational, multicenter, international registry collecting de-identified clinical and genetic information from patients with homozygous Familial Hypercholesterolemia (HoFH) worldwide. Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data reflecting current rather than historic practice, patients who died or were lost to follow-up prior to 2010 are excluded. Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results of a genetic test), genetic results, (cardiovascular) medical history, relevant family history, physical examination, laboratory measurements, lipid lowering treatment and cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment and at time of best lipid profile (if this is different from time at enrolment). Data are collected using pre-definite electronic case report forms to ensure uniformity of data collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age, etc)

Conditions

Interventions

TypeNameDescription
OTHERDemographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.

Timeline

Start date
2017-01-24
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2021-03-24
Last updated
2025-12-18

Locations

4 sites across 3 countries: United States, Netherlands, South Africa

Source: ClinicalTrials.gov record NCT04815005. Inclusion in this directory is not an endorsement.